1- https://doi.org/10.7883/yoken.jjid.2021.416
Negative Results of Nucleic Acid Amplification Tests for SARS-CoV-2 in Clinical Practice May Vary among Six Molecular Assays in Patients with COVID-19.
Translate Article 
Several commercial nucleic acid amplification tests (NAATs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. We used 6 kits available in Japan in 13 NAAT-positive specimens with crossing point values >36 and 7 NAAT-negative specimens from patients with coronavirus disease 2019 (COVID-19), and their results were compared. Specimens positive in ≥2 assays were considered true-positive and examined for concordance with the specimen results. The SARS-CoV-2 Detection Kit -Multi- (Toyobo M; Toyobo, Osaka, Japan) using extracted RNA had the highest concordance (κ = 1.00). This was followed by Cobas® SARS-CoV-2 (Roche, Basel, Switzerland) (κ = 0.79). There was a weak correlation between the number of negative results for each kit and the number of days between onset and testing (Spearman rank correlation: ρ = 0.44; P < 0.05). We believe that the variations in results among kits for specimens with low viral loads should not be problematic when these kits are used for screening infectious patients because these variations are more likely to be observed in specimens tested many days after onset (i.e., those that have lost their infectivity). However, it may be better to use a test for suspected late-stage COVID-19 with a low viral load, such as Toyobo M or Cobas.
- Research Article
- 54
- 10.1053/j.gastro.2020.07.043
- Jul 28, 2020
- Gastroenterology
AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
- Research Article
- 22
- 10.31635/ccschem.020.202000322
- Jul 10, 2020
- CCS Chemistry
Coronavirus disease 2019 (COVID-19) is caused by a novel strain of coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused a global pandemic rapidly s...
- Research Article
- 23
- 10.12968/hmed.2020.0156
- Apr 2, 2020
- British Journal of Hospital Medicine
Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.
- Research Article
- 23
- 10.1097/cm9.0000000000000899
- Jul 5, 2020
- Chinese Medical Journal
In December 2019, a novel coronavirus was identified in Wuhan City, Hubei Province, China and later the disease was named coronavirus disease 2019 (COVID-19). On March 11, 2020, the World Health Organization (WHO) officially announced that COVID-19 had reached global pandemic status. This article summarized the understanding of the etiology, pathogenesis, epidemiology, clinical characteristics, diagnosis, treatment, rehabilitation, and prevention and control measures of COVID-19 based on the available data and anti-epidemic experience in China.
- Discussion
- 16
- 10.1016/j.jinf.2020.11.023
- Nov 26, 2020
- The Journal of Infection
Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR
- Research Article
- 5
- 10.1097/mcp.0000000000000771
- Mar 1, 2021
- Current Opinion in Pulmonary Medicine
Editorial: Coronavirus disease 2019 (COVID-19) - advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges.
- Research Article
- 7
- 10.1038/s41436-021-01113-0
- Jun 1, 2021
- Genetics in Medicine
The intersection of genetics and COVID-19 in 2021: preview of the 2021 Rodney Howell Symposium
- Research Article
- 85
- 10.1111/ajt.16000
- Jun 11, 2020
- American Journal of Transplantation
Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"
- Front Matter
- 16
- 10.1053/j.gastro.2020.03.046
- Mar 27, 2020
- Gastroenterology
Responding to COVID-19: Perspectives From the Chinese Society of Gastroenterology
- Research Article
- 23
- 10.1053/j.gastro.2021.09.009
- Sep 8, 2021
- Gastroenterology
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
- Research Article
- 34
- 10.1053/j.ackd.2020.07.004
- Jul 17, 2020
- Advances in Chronic Kidney Disease
COVID-19 in Kidney Transplantation: Outcomes, Immunosuppression Management, and Operational Challenges.
- Front Matter
- 60
- 10.1016/j.ijid.2020.11.189
- Dec 1, 2020
- International Journal of Infectious Diseases
COVID-19: A PCR-defined pandemic
- Research Article
- 5
- 10.1016/j.ajodo.2020.08.010
- Sep 21, 2020
- American Journal of Orthodontics and Dentofacial Orthopedics
COVID-19: What do we know?
- Discussion
- 24
- 10.1002/uog.24809
- Jan 13, 2022
- Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
Does COVID-19 cause pre-eclampsia?
- Peer Review Report
- 4
- 10.7554/elife.64188.sa2
- Apr 13, 2021
Background:To understand a causal role of modifiable lifestyle factors in angiotensin-converting enzyme 2 (ACE2) expression (a putative severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] receptor) across 44 human tissues/organs, and in coronavirus disease 2019 (COVID-19) susceptibility and severity, we conducted a phenome-wide two-sample Mendelian randomization (MR) study.Methods:More than 500 genetic variants were used as instrumental variables to predict smoking and alcohol consumption. Inverse-variance weighted approach was adopted as the primary method to estimate a causal association, while MR-Egger regression, weighted median, and MR pleiotropy residual sum and outlier (MR-PRESSO) were performed to identify potential horizontal pleiotropy.Results:We found that genetically predicted smoking intensity significantly increased ACE2 expression in thyroid (β=1.468, p=1.8×10−8), and increased ACE2 expression in adipose, brain, colon, and liver with nominal significance. Additionally, genetically predicted smoking initiation significantly increased the risk of COVID-19 onset (odds ratio=1.14, p=8.7×10−5). No statistically significant result was observed for alcohol consumption.Conclusions:Our work demonstrates an important role of smoking, measured by both status and intensity, in the susceptibility to COVID-19.Funding:XJ is supported by research grants from the Swedish Research Council (VR-2018–02247) and Swedish Research Council for Health, Working Life and Welfare (FORTE-2020–00884).
